Literature DB >> 25549831

Using Human Induced Pluripotent Stem Cells to Model Skeletal Diseases.

Emilie Barruet1, Edward C Hsiao2.   

Abstract

Musculoskeletal disorders affecting the bones and joints are major health problems among children and adults. Major challenges such as the genetic origins or poor diagnostics of severe skeletal disease hinder our understanding of human skeletal diseases. The recent advent of human induced pluripotent stem cells (human iPS cells) provides an unparalleled opportunity to create human-specific models of human skeletal diseases. iPS cells have the ability to self-renew, allowing us to obtain large amounts of starting material, and have the potential to differentiate into any cell types in the body. In addition, they can carry one or more mutations responsible for the disease of interest or be genetically corrected to create isogenic controls. Our work has focused on modeling rare musculoskeletal disorders including fibrodysplasia ossificans progressive (FOP), a congenital disease of increased heterotopic ossification. In this review, we will discuss our experiences and protocols differentiating human iPS cells toward the osteogenic lineage and their application to model skeletal diseases. A number of critical challenges and exciting new approaches are also discussed, which will allow the skeletal biology field to harness the potential of human iPS cells as a critical model system for understanding diseases of abnormal skeletal formation and bone regeneration.

Entities:  

Keywords:  Directed differentiation; Fibrodysplasia ossificans progressiva; Human iPS cells; Mineralization; Ossification; Skeletal diseases

Mesh:

Substances:

Year:  2016        PMID: 25549831     DOI: 10.1007/7651_2014_171

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

Review 1.  Stem Cells in Skeletal Tissue Engineering: Technologies and Models.

Authors:  Mark T Langhans; Shuting Yu; Rocky S Tuan
Journal:  Curr Stem Cell Res Ther       Date:  2016       Impact factor: 3.828

Review 2.  Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review.

Authors:  Farshid Bastami; Pantea Nazeman; Hamidreza Moslemi; Maryam Rezai Rad; Kazem Sharifi; Arash Khojasteh
Journal:  Cell Prolif       Date:  2016-12-01       Impact factor: 6.831

3.  Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation.

Authors:  Zixue Jin; Jordan Kho; Brian Dawson; Ming-Ming Jiang; Yuqing Chen; Saima Ali; Lindsay C Burrage; Monica Grover; Donna J Palmer; Dustin L Turner; Philip Ng; Sandesh Cs Nagamani; Brendan Lee
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 4.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

Review 5.  Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases.

Authors:  Liang Shi; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2016-08

6.  Generation of urine-derived induced pluripotent stem cells from a patient with phenylketonuria.

Authors:  Zijuan Qi; Yazhou Cui; Liang Shi; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-05

Review 7.  iPS cell technologies and their prospect for bone regeneration and disease modeling: A mini review.

Authors:  Maria Csobonyeiova; Stefan Polak; Radoslav Zamborsky; Lubos Danisovic
Journal:  J Adv Res       Date:  2017-03-06       Impact factor: 10.479

Review 8.  Mesenchymal Stem Cell Therapy for Bone Regeneration.

Authors:  Yuan-Zhe Jin; Jae Hyup Lee
Journal:  Clin Orthop Surg       Date:  2018-08-22

Review 9.  Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases.

Authors:  Clara Sanjurjo-Rodríguez; Rocío Castro-Viñuelas; María Piñeiro-Ramil; Silvia Rodríguez-Fernández; Isaac Fuentes-Boquete; Francisco J Blanco; Silvia Díaz-Prado
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.